Application and Progress of Insulin Delivery Devices in Diabetes Management
With continuous advancements in diabetes management technology, insulin delivery devices are playing an increasingly important role in diabetes treatment. The application of various technologies, such as insulin pens and insulin pumps, plays an essential role in the management of type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Insulin pens, known for their convenience and dosing accuracy, have been widely used among T2DM patients, and recent developments in smart insulin pens have further improved patient adherence and glycemic control. Insulin pumps, particularly patch pumps, provide more precise blood glucose management for T1DM and some T2DM patients, significantly reducing glycemic variability and the risk of hypoglycemia. As an innovative insulin delivery device, patch pumps are characterized by their compact, lightweight, and tubeless design, making them particularly suitable for patients seeking a discreet and convenient user experience. Nevertheless, further optimization is needed in the display of dosage and key parameters to ensure real-time and clear monitoring of insulin delivery, thereby assisting patients and clinicians in making timely adjustments to treatment plans. This review summarizes the advantages and disadvantages of different types of insulin delivery systems and discusses their future directions in clinical applications. The further advancement of these systems holds promise for providing safer, more convenient, and precise treatment experiences for diabetes management.
[1] Chinese Diabetes Society of Chinese Medical Association, 2025, Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition). Chinese Journal of Diabetes, 17(1): 16–139.
[2] Chinese Diabetes Society, Endocrinology and Metabolism Physicians Branch of Chinese Medical Doctor Association, Chinese Society of Endocrinology, et al., 2022, Chinese Clinical Guidelines for Type 1 Diabetes (2021 Edition). Chinese Journal of Diabetes, 14(11): 1143–1250.
[3] Chinese Society of Endocrinology, Chinese Diabetes Society, Endocrinology and Metabolism Physicians Branch of Chinese Medical Doctor Association, 2021, Chinese Guidelines for Insulin Pump Therapy (2021 Edition). Chinese Journal of Endocrinology and Metabolism, 37(8): 679–701.
[4] Chinese Diabetes Society, 2021, Clinical Application Guidelines for Blood Glucose Monitoring in China (2021 Edition). Chinese Journal of Diabetes, 13(10): 936–948.
[5] Chinese Society of Endocrinology, National Innovation Center for High-Performance Medical Devices, 2024, Expert Consensus on Clinical Application of Ambulatory Glucose Profile (2023 Edition). Chinese Journal of Diabetes, 16(2): 190–201.
[6] Sperling M, Laffel L, 2022, Current Management of Glycemia in Children with Type 1 Diabetes Mellitus. The New England Journal of Medicine, 386(12): 1155–1164.
[7] Ge K, Li J, Zeng L, et al., 2022, Comparing the Effectiveness of Continuous Subcutaneous Insulin Infusion with Multiple Daily Insulin Injection for Patients with Type 1 Diabetes Mellitus Evaluated by Retrospective Continuous Glucose Monitoring: A Real-World Data Analysis. Frontiers in Public Health, 10: 990281.
[8] Klonoff D, Kerr D, 2018, Smart Pens Will Improve Insulin Therapy. Journal of Diabetes Science and Technology, 12(3): 551–553.
[9] Reznik Y, Cohen O, Aronson R, et al., 2014, Insulin Pump Treatment Compared with Multiple Daily Injections for Treatment of Type 2 Diabetes (OpT2mise): A Randomised Open-Label Controlled Trial. The Lancet, 384(9950): 1265–1272.
[10] Aronson R, Reznik Y, Conget I, et al., 2016, Sustained Efficacy of Insulin Pump Therapy Compared with Multiple Daily Injections in Type 2 Diabetes: 12-Month Data from the OpT2mise Randomized Trial. Diabetes, Obesity and Metabolism, 18(5): 500–507.
[11] Chinese Insulin Secretion Research Group, 2021, Expert Consensus on Short-Term Intensive Insulin Therapy for Reversal of Type 2 Diabetes. Chinese Journal of Diabetes, 13(10): 949–959.
[12] Weng J, Li Y, Xu W, et al., 2008, Effect of Intensive Insulin Therapy on Beta-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes. The Lancet, 371(9626): 1753–1760.
[13] Gu W, Liu Y, Chen Y, et al., 2017, Multicentre Randomized Controlled Trial with Sensor-Augmented Pump vs Multiple Daily Injections in Hospitalized Patients with Type 2 Diabetes in China: Time to Reach Target Glucose. Diabetes & Metabolism, 43(4): 359–363.
[14] Sutton D, Higdon C, Nikkel C, et al., 2018, Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis. Advances in Therapy, 35(5): 631–643.
[15] Feig D, Corcoy R, Donovan L, et al., 2018, Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care, 41(12): 2471–2479.
